Claudia Ulbrich, MD, is a serial entrepreneur and senior executive with over 25 years of experience in leading and building private and public biotech companies together with high-performing teams. Her track record includes successful multi-billion EUR exits, pharma partnerships, and IPOs. Most recently she served as CEO of Cardior Pharmaceuticals, which was acquired by Novo Nordisk in 2024.
In addition to serving on the Board of economic and industry associations, Claudia is a Non-executive Director and Chair on the Board of iDEL therapeutics, GER, a Non-executive Director on the Board of CoraBioSciences, UK, and a Venture Partner at BiomedVC. As Chair of the Board of Tridek-One Therapeutics, she contributes her deep industry expertise with a focus on corporate and business development, strategic operations, and clinical development strategy.